$CVSBullishMed

Company Announcement

Kelso Group Holdings provided a May 2026 portfolio update. Gross investments were ~£19.4m and net assets ~£14.0m (3.0p/share) at 29 May 2026, up ~35% since start of 2026; it expects H1 pre-tax profit of ~£3.0m. Kelso increased stakes in The Works (8%), CVS (~230k shares) and Capita (400k shares, ~8% of gross). It holds 2.1m NCC shares (~15%); NCC completed the Escode sale to TDR Capital for £275m EV and plans to return £185m. Kelso sold Filtronic for a ~119% realised gain. Total shares/voting ri

Med
Bullish
ahead of NCC unaudited results on 11 June 2026; portfolio update pre-market today
Generally supportive for holdings with disclosed catalysts (NCC sale/capital return; CVS buyback/refinance).

Refinancing plus buyback authorization can tighten float and improve equity support for CVS.

Kelso cites CVS’s acquisitions, £350m debt refinance, and a new £50m share buyback program, alongside Kelso increasing its stake.

Near-term supportive; buyback headlines can attract incremental demand.

Background

Kelso Group Holdings is a concentrated UK investment vehicle; this release is a portfolio performance and holdings update covering multiple underlying UK public companies.

Why it matters

The most tradable catalysts are NCC’s completed Escode sale and stated intention to return proceeds, plus CVS’s refinance and £50m buyback program. Other names are mainly position changes and qualitative turnaround commentary.

Market relevance

Traders can use the disclosed corporate actions (NCC sale/capital return; CVS buyback/refinance) for near-term positioning, while other items are secondary read-through from Kelso’s portfolio changes.

Market effects

Reinforces UK small/mid-cap turnaround and capital-return narratives (divestitures, refinancing, buybacks) rather than a broad sector shock.

Primarily UK-listed sentiment; could influence UK small/mid-cap risk appetite via portfolio read-through.

Low; events are company-specific within UK equities with limited direct global linkage.

Alternative perspectives

Kelso’s portfolio actions may reflect relative-value timing rather than fundamental re-rating; realized gains/exits can be profit-taking, not a durable trend.

For NCC, the capital-return method is still pending Board decision after the Cyber review—execution details could disappoint versus market expectations.

Key entities

  • Kelso Group Holdings Plc

    Main market listed investment vehicle providing a May 2026 portfolio update and holding changes.

  • TheWorks.co.uk plc

    Underlying holding where Kelso cites a guidance upgrade and increased stake.

  • NCC Group plc

    Underlying holding where Kelso cites completion of Escode sale and planned shareholder return.

  • CVS Group plc

    Underlying holding where Kelso cites acquisitions, £350m refinance, and £50m buyback.

  • Capita plc

    Underlying holding where Kelso increased exposure and highlights turnaround progress.

Related articles

$LLYMed

CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors

CVS Caremark, CVS Health’s PBM, said it will cover Eli Lilly’s Zepbound starting Oct. 1, reversing a prior formulary removal, and will cover Lilly’s oral GLP-1 pill Foundayo effective June 1. Lilly said this brings coverage across the three largest U.S. PBMs. In Q1, Lilly reported sales up 56% to $19.8B and adjusted EPS up 156% to $8.55.

$CVSMed

Is CVS Health Stock Outperforming the S&P 500?

CVS Health (CVS) has a $115.6B market cap and, according to the article, has outperformed the S&P 500 over multiple periods. Shares are down 9.1% from a $98.43 52-week high but up 9.6% in three months and 40.7% over 52 weeks. After FY2026 Q1 results (revenue $100.4B, adj. EPS $2.57), CVS shares rose 7.7%; the company raised FY2026 adj. EPS guidance to $7.30–$7.50. Analysts rate it “Strong Buy” with a $102.26 mean target.

$LLYMed

Eli Lilly Wins Back CVS Health, Reverting Novo Advantage

Eli Lilly said it reached an agreement with CVS Health to extend coverage of its approved GLP-1 drugs through CVS Caremark. The change reverses CVS’s prior 2025 decision making Novo Nordisk’s GLP-1 preferred and excluding Lilly’s Zepbound; CVS spokesperson said clients will have equal access and consumers will face the same co-pays. Caremark coverage starts June 1 for Foundayo and Oct. 1 for Zepbound.

$ABBVLow

The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains

The S&P 500 was up about 11% entering Tuesday, helped by tech gains amid Iran-war and oil-price concerns and expectations of higher interest rates. The article highlights dividend stocks it says look undervalued: AbbVie (forward P/E 15, dividend yield 3.3%, free cash flow just under $20B), CVS Health (forward P/E 12, yield 2.9%, free cash flow $7.4B vs dividends $3.4B), and Verizon (forward P/E just under 10, yield 5.9%, free cash flow nearly $20B vs annual dividends $11.5B; adjusted earnings gr